Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Operating Leases (2019 - 2025)

Historic Operating Leases for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $85.1 million.

  • Allogene Therapeutics' Operating Leases fell 797.95% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year decrease of 797.95%. This contributed to the annual value of $90.8 million for FY2024, which is 458.89% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Operating Leases of $85.1 million as of Q3 2025, which was down 797.95% from $87.0 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Operating Leases peaked at $101.1 million during Q4 2022, and registered a low of $53.9 million during Q3 2021.
  • Moreover, its 5-year median value for Operating Leases was $90.8 million (2024), whereas its average is $84.5 million.
  • In the last 5 years, Allogene Therapeutics' Operating Leases skyrocketed by 8071.97% in 2022 and then crashed by 797.95% in 2025.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Operating Leases stood at $73.1 million in 2021, then skyrocketed by 38.28% to $101.1 million in 2022, then fell by 5.94% to $95.1 million in 2023, then fell by 4.59% to $90.8 million in 2024, then dropped by 6.19% to $85.1 million in 2025.
  • Its Operating Leases stands at $85.1 million for Q3 2025, versus $87.0 million for Q2 2025 and $88.9 million for Q1 2025.